AI drug discovery company Elix and Axcelead Drug Discovery Partners (ADDP) said on September 9 that they have struck a collaborative research deal to discover novel targeted protein degraders (TPDs). The partners will build new AI drug discovery models using…
To read the full story
BUSINESS
- Ex-Takeda CEO Weber Joins Rakuten Medical as Vice Chairman
September 10, 2026
- 3 Chugai Researchers Win Lasker Award for Hemlibra Discovery
September 10, 2026
- Elix, Axcelead DDP Forge Pact on Novel Protein Degraders
September 10, 2026
- CMIC Scraps Application Forms, Brings AI Avatars into New Grad Hiring
September 10, 2026
- Teijin, Shinshu University Link Arms on CAR-T Manufacturing
September 10, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





